Marinus Pharmaceuticals initiated at Jefferies

Marinus Pharmaceuticals initiated with a Buy at Jefferies. Jefferies analyst Andrew Tsai started Marinus Pharmaceuticals with a Buy rating and $10 price target. Marinus is an inexpensive name that offers a favorable setup at current price levels, Tsai tells investors in a research note. The stock’s risk/reward for is “skewed heavily towards the upside” as the Street appears to underappreciate the company having multiple shots on goal, adds the analyst. He believes the Phase II postpartum depression readout in the first half of 2019 could rally stock up to 50% if positive.
https://thefly.com/landingPageNews.php?id=2874319